Role of 2-[18F] Fluoro-2-Deoxy-D-Glucose-Positron Emission Tomography/Computed Tomography in the Post-Therapy Surveillance of Breast Cancer
Open Access
- 17 December 2014
- journal article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 9 (12), e115127
- https://doi.org/10.1371/journal.pone.0115127
Abstract
To evaluate the usefulness of 2-[18F] fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography (FDG-PET/CT) in the early detection of breast cancer tumor recurrences and its role in post-therapy surveillance. FDG-PET/CT was performed on patients with increased serum CA 15-3 levels and/or clinical/radiologic suspicion of recurrence. A group of asymptomatic patients who underwent FDG-PET/CT in the post-therapy surveillance of breast cancer served as the controls. The results were analyzed based on the patients' histological data, other imaging modalities and/or clinical follow-up. Recurrence was defined as evidence of recurrent lesions within 12 months of the FDG-PET/CT scan. Based on elevated serum CA15-3 levels (n = 31) and clinical/radiologic suspicion (n = 40), 71 scans were performed due to suspected recurrence, whereas 69 scans were performed for asymptomatic follow-up. The sensitivity and specificity of FDG-PET/CT were 87.5% and 87.1% in the patients with suspected recurrence and 77.8% and 91.7% in the asymptomatic patients. The positive predictive value in the patients with suspected recurrence (mainly due to elevated serum CA 15-3 levels) was higher than that in asymptomatic patients (P = 0.013). Recurrences were proven in 56.3% (40/71) of the patients with suspected recurrence and in 13% (9/69) of the asymptomatic patients (PPP<0.001). FDG-PET/CT was able to detect recurrence, and the results altered the intended patient management in the post-therapy surveillance of breast cancer. FDG-PET/CT should be used as a priority in patients with increased serum CA 15-3 levels, or with clinical/radiologic suspicion of recurrence, and might be useful for asymptomatic patients.Keywords
This publication has 24 references indexed in Scilit:
- Clinical utility of F-18 FDG PET/CT in recurrent breast carcinomaNuclear Medicine Communications, 2012
- 18F-FDG-PET/CT in patients with breast cancer and rising Ca 15-3 with negative conventional imaging: A multicentre studyEuropean Journal of Radiology, 2011
- Tumour markers and FDG PET/CT for prediction of disease relapse in patients with breast cancerEuropean Journal of Nuclear Medicine and Molecular Imaging, 2010
- Positron emission tomography/computed tomography in the management of recurrent/metastatic breast cancer: a large retrospective study from the Royal Marsden HospitalAnnals Of Oncology, 2010
- American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast CancerJournal of Clinical Oncology, 2007
- F-18-Fluoro-2-Deoxyglucose Positron Emission Tomography/Computed Tomography in the Follow-up of Breast Cancer With Elevated Levels of Tumor MarkersJournal of Computer Assisted Tomography, 2007
- Partial-Volume Effect in PET Tumor ImagingJournal of Nuclear Medicine, 2007
- A meta-analysis of FDG-PET for the evaluation of breast cancer recurrence and metastasesBreast Cancer Research and Treatment, 2005
- Impact of FDG PET on Defining the Extent of Disease and on the Treatment of Patients with Recurrent or Metastatic Breast CancerAmerican Journal of Roentgenology, 2004
- Ca 15-3 in the follow-up of localised breast cancer: a prospective studyEuropean Journal Of Cancer, 2002